Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2016 version)].

Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 Jul 2016

Shi Yuankai, Sun Yan, Ding Cuimin, Wang Ziping, Wang Changli, Bai Chong, Bai Chunxue, Feng Jifeng, Liu Xiaoqing, Li Fang, Yang Yue, Shu Yongqian, Wu Milu, He Jianxing, Zhang Yiping, Zhang Shucai, Chen Gongyan, Luo Honghe, Luo Rongcheng, Zhou Caicun, Pang Qingsong, Hu Xingsheng, Zhao Hong, Zhao Qiong, Gu Aiqin, Ling Yang, Huang Cheng, Han Baohui, Jiao Shunchang, Jian Hong

Abstract excerpt

No abstract is available from the source.

Topics

Join the communities discussing this publication.

Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
China
Consensus
Crown Ethers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 27339727
DOI: 10.3779/j.issn.1009-3419.2016.07.12
PMCID: PMC5972963

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2016 version)].PMID 27339727Read ↗

[Expert consensus on icotinib as adjuvant therapy for non-small cell lung cancer].Semantic proximity Read ↗

Status and progress of Icotinib in treatment of EGFR-mutant non-small cell lung carcinomaSemantic proximity Read ↗

Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.Semantic proximity Read ↗

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.Semantic proximity Read ↗

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.Semantic proximity Read ↗

[The Diagnosis and Treatment Guideline of Chinese Patients with EGFR Mutation and ALK Fusion Gene-Positive Non-Small Cell Lung Cancer (2013 Version)].Semantic proximity Read ↗

[Clinical Analysis of Icotinib on Beneficiary of Advanced Non-small Cell Lung Cancer with EGFR Common Mutation].Semantic proximity Read ↗

Comparison of the efficacy and safety of icotinib monotherapy and combined therapy of icotinib and vinorelbine as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A retrospective studySemantic proximity Read ↗

The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study.Semantic proximity Read ↗

[Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer].Semantic proximity Read ↗

Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.